Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child

Antiviral Therapy

Volumn 9, Issue 1, 2004, Pages 97-104

  Stránská, Růzena ^a   Van Loon, Anton M ^a   Bredius, Robbert G M ^b   Polman, Merjo ^a   Nienhuis, Elske ^a   Beersma, Matthias F C ^b   Lankester, Arjan C ^b   Schuurman, Rob ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ARGININE; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; SERINE; THYMIDINE KINASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; CROSS RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE DEFICIENCY; MALE; NONHUMAN; PRIORITY JOURNAL; SCHOOL CHILD; STRUCTURAL GENE; VIRUS ISOLATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; CHILD; DNA-DIRECTED DNA POLYMERASE; GENOTYPE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; INFANT, NEWBORN; LEUKEMIA, MYELOID, CHRONIC; MALE; MICROBIAL SENSITIVITY TESTS; MOUTH; NOSE; PHYLOGENY; SPUTUM; STEM CELL TRANSPLANTATION; THYMIDINE KINASE;

EID: 1542349069     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Chen Y, Scieux C, Garrait V, Socie G, Rocha V, Molina JM, Thouvenot D, Morfin F, Hocqueloux L, Garderet L, Esperou H, Selimi F, Devergie A, Leleu G, Aymard M, Morinet F, Gluckman E & Ribaud P. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clinical Infectious Diseases 2001; 31:927-935.
2. Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M & Darby G. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrobial Agents & Chemotherapy 1998; 42:868-872.
3. Lina B, Thouvenot D, Danve C, Morfin F, Boucher A, Berlin I & Aymard M. Implementation of surveillance network of the herpes simplex virus resistance to antiviral drugs. European Virology 2000. Glasgow, Scotland, 17-21 September 2000. Abstract O-086.
4. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR & Balfour HH. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Annals of Internal Medicine 1990; 112:416-422.
5. Langston AA, Redei I, Caliendo AM, Somani J, Hutcherson D, Lonial S, Bucur S, Cherry J, Allen A & Waller EK. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 2002; 99:1085-1088.
6. van Kraaij MG, Verdonck LF, Rozenberg-Arska M & Dekker AW. Early infections in adults undergoing matched related and matched unrelated/ mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplantation 2002; 30:303-309.
7. Morfin F, Thouvenot D, Souillet G, Michallet M & Aymard M. Acyclovir-resistant (ACV-R) herpes viruses (HSV, VZV) in bone marrow transplantation patients. Progress in Clinical Virology V Budapest, Hungary, 1-5 September 1999. Abstract 429.
8. Arnulf B, Chebbi F, Lefrere F, Ait AZ, Varet B & Fillet AM. Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient. Bone Marrow Transplantation 2001; 28:799-801.
9. Bestman-Smith J, Schmit I, Papadopoulou B & Boivin G. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. Journal of Virology 2001; 75:3105-3110.
10. Gaudreau A, Hill E, Balfour HH Jr, Erice A & Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. Journal of Infectious Diseases 1998; 178:297-303.
11. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M & Thouvenot D. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. Journal of Infectious Diseases 2000; 182:290-293.
12. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL & Knipe DM. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proceedings of National Academy of Sciences, USA 1989; 86:4736-4740.
13. Efstathiou S, Kemp S, Darby G & Minson AC. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. Journal of General Virology 1989; 70:869-879.
14. Larder BA & Darby G. Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir. Antimicrobial Agents & Chemotherapy 1986; 29:894-898.
15. Larder BA & Darby G. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities. Virology 1985; 146:262-271.
16. Schmit I & Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. Journal of Infectious Diseases 1999; 180:487-490.
17. Chibo D, Mijch A, Doherty R & Birch C. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient. Journal of Clinical Virology 2002; 25:165-170.
18. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL & Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Annals of Internal Medicine 1989; 111:893-899.
19. Hwang CB, Ruffner KL & Coen DM. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. Journal of Virology 1992; 66:1774-1776.
20. Collins P, Larder BA, Oliver NM, Kemp S, Smith IW & Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. Journal of General Virology 1989; 70:375-382.
21. Field HJ & Coen DM. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. Journal of Virology 1986; 60:286-289.
22. Larder BA & Darby G. Virus drug-resistance: mechanisms and consequences. Antiviral Research 1984; 4:1-42.
23. Collins P & Darby G. Laboratory Studies of Herpes simplex virus strains resistant to acyclovir. Reviews in Medical Virology 1991; 1:19-28.
24. Schilham MW, Claas EC, van Zaane W, Heemskerk B, Vossen JM, Lankester AC, Toes RE, Echavarria M, Kroes AC & van Tol MJ. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clinical Infectious Diseases 2002; 35:526-532.
25. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, Noel JC, Wulfsohn MS, Rooney JF, Jaffe HS & De Clercq E. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clinical Infectious Diseases 2001; 33:597-602.
26. Schaffer PA, Aron GM, Biswal N & Benyesh-Melnick M. Temperature-sensitive mutants of herpes simplex virus type 1: isolation, complementation and partial characterization. Virology 1973; 52:57-71.
27. Stranska R, van Loon AM, Polman M & Schuurman R. Application of real-time PCR for determination of antiviral drug susceptibility of herpes simplex virus. Antimicrobial Agents & Chemotherapy 2002; 46:2943-2947.
28. Andrei G, Snoeck R, De Clercq E, Esnouf R, Fiten P & Opdenakker G. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. Journal of General Virology 2001; 81:639-48.
29. Kumar S, Tamura K, Jakobsen IB & Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 2001; 17:1244-1245.
30. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE & Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. Journal of Infectious Diseases 2000; 181:2055-2058.
31. Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzarini J, Sadzot-Delvaux C, Tricot G, Clumeck N & De Clercq E. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clinical Infectious Diseases 1994; 18:570-578.
32. Larder BA, Kemp SD & Darby G. Related functional domains in virus DNA polymerases. EMBO Journal 1987; 6:169-175.
33. Gibbs JS, Chiou HC, Bastow KF, Cheng YC & Coen DM. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proceedings of National Academy of Sciences, USA 1988; 85:6672-6676.
34. Bestman-Smith J & Boivin G. Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. Journal of Medical Virology 2002; 67:88-91.
35. Bestman-Smith J & Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. Journal of Virology 2003; 77:7820-7829.
36. Evans JS, Lock KP, Levine BA, Champness JN, Sanderson MR, Summers WC, McLeish PJ & Buchan A. Herpesviral thymidine kinases: laxity and resistance by design. Journal of General Virology 1998; 79:2083-2092.
37. Champness JN, Bennett MS, Wien F, Visse R, Summers WC, Herdewijn P, De Clerq E, Ostrowski T, Jarvest RL & Sanderson MR. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with acyclovir and other ligands. Proteins 1998; 32:350-361.
38. Black ME & Loeb LA. Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro. Biochemistry 1993; 32:11618-11626.
39. Roberts GB, Fyfe JA, Gaillard RK & Short SA. Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. Journal of Virology 1991; 65:6407-6413.
40. Sawyer MH, Inchauspe G, Biron KK, Waters DJ, Straus SE & Ostrove JM. Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus. Journal of General Virology 1988; 69:2585-2593.
41. Parris DS & Harrington JE. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrobial Agents & Chemotherapy 1982; 22:71-77.
42. Hwang CB & Chen HJ. An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase. Gene 1995; 152:191-193.
43. Blot N, Schneider P, Young P, Janvresse C, Dehesdin D, Tron P & Vannier JP. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplantation 2000; 26:903-905.